DOI: 10.1007/s00259-017-3682-8Pages: 1-2

Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging

1. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Nuclear Medicine Unit

2. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Unit of Biostatistics and Clinical Trials

Correspondence to:
Giovanni Paganelli
Email: giovanni.paganelli@irst.emr.it

Close

Abstract

To access the full text, please Sign in

If you have institutional access, please click here

  • Accepted: Mar 15, 2017
  • Online: Mar 22, 2017

Article Tools

eanm
EJNMMI Ad